Paradigm Biocapital Advisors LP Immatics N.V. Transaction History
Paradigm Biocapital Advisors LP
- $2.77 Billion
- Q3 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,904,862 shares of IMTX stock, worth $26.7 Million. This represents 1.61% of its overall portfolio holdings.
Number of Shares
3,904,862
Previous 3,421,965
14.11%
Holding current value
$26.7 Million
Previous $39.8 Million
12.05%
% of portfolio
1.61%
Previous 1.61%
Shares
6 transactions
Others Institutions Holding IMTX
# of Institutions
101Shares Held
75.8MCall Options Held
238KPut Options Held
727K-
Rtw Investments, LP New York, NY10MShares$68.5 Million1.82% of portfolio
-
Wellington Management Group LLP Boston, MA9.68MShares$66.3 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$55.4 Million2.41% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.38MShares$50.6 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$44.1 Million0.79% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $522M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...